ClinicalTrials.gg
RecruitingNCT07026318ANGEL-DRUGUpdated Sep 22, 2025

Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke

An interventional study of Tirofiban and Placebo in Acute Ischemic Stroke, sponsored by Beijing Anzhen Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
716
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies testing tirofiban in Ischemic Stroke — 13 open to participants now, 13 under way, 9 of them phase 3. Tirofiban · Ischemic Stroke.

Planned enrollment
9th of 21
716 · median 564
Started
2025
with 2 others
No phase
2 of 21
2 open now
Primary completion
2027-03
later than 7 of 12 live
Registered
14th of 21
by date
Lead sponsor
2 of 21
Beijing Anzhen Hospital

Among the 21 studies testing tirofiban in Ischemic Stroke, this one is the 9th largest by planned enrollment, is one of 3 that started in 2025, is one of 2 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 14th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

13 of the 21 studies testing tirofiban in Ischemic Stroke are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About tirofiban

Tirofiban: first FDA approval 1998 (AGGRASTAT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tirofiban in Ischemic Stroke, or all of them as a file.
02

Study summary

This randomized controlled trial aims to evaluate whether adjunctive tirofiban therapy combined with endovascular treatment (EVT) improves neurological outcomes in patients with acute large vessel occlusion due to large-artery atherosclerosis. Patients will be randomized to receive either tirofiban or matching placebo after EVT. The primary efficacy endpoint is the proportion of patients achieving functional independence (modified Rankin Scale 0-2) at 90±7 days, while the safety endpoint is the probability of symptomatic intracranial hemorrhagewithin 48 hours after randomization.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Acute Ischemic Stroke
  • Tirofiban
  • placebo
  • Randomized Controlled Trial
  • Intracranial Atherosclerotic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Pre-stroke modified Rankin Scale (mRS) score of 0-1
  3. Acute ischemic stroke symptoms present within 24 hours of last known well time
  4. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6
  5. Anterior circulation: Alberta Stroke Program Early CT Score (ASPECTS) ≥6 Posterior circulation: pc-ASPECTS ≥6
  6. Occlusion of intracranial internal carotid artery (ICA), M1 segment of middle cerebral artery (MCA), V4 segment of vertebral artery, or basilar artery
  7. Clinical care team plans to perform endovascular thrombectomy (EVT)
  8. Subject or legally authorized representative can provide
  9. Residual stenosis ≥50% without planned angioplasty/stenting

Exclusion criteria

Exclusion Criteria:

  1. Intracranial hemorrhage confirmed by imaging prior to randomization, or major intracranial hemorrhage on intraprocedural flat-panel CT
  2. Gastrointestinal or genitourinary bleeding within 30 days post-stroke onset, or major surgery within 14 days
  3. Bleeding diathesis including coagulopathy ( \<100×10⁹/L, >50s, or INR >2.0), DOAC use within 48 hours, or history of HIT
  4. Pregnancy or lactation at admission
  5. to radiographic contrast agents, nickel, titanium or their alloys
  6. \<6 months
  7. Pre-existing neurological/psychiatric conditions that may confound assessment
  8. Severe renal insufficiency ( \<30mL/min or Scr >220μmol/L [2.5mg/dL])
  9. Arterial tortuosity or anomalies preventing device delivery
  10. Unlikely to complete 90-day follow-up
  11. Any confirmed cardioembolic source (including atrial fibrillation, valvular disease, intracardiac thrombus, recent MI, cardiomyopathy with EF \<30%, etc.)
  12. Tirofiban or other GP IIb/IIIa inhibitor use before randomization or other GP IIb/IIIa inhibitor used post treatment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
716 participants (estimated)

Study arms

  • Experimental
    Tirofiban group

    Receive Tirofiban treatment following endovascular therapy

    Drug: Tirofiban

  • Placebo comparator
    placebo group

    Receive placebo treatment after endovascular therapy.

    Drug: Placebo

Interventions

  • After endovascular treatment, tirofiban is infused at a rate of 0.4 μg/kg/min for 30 minutes, followed by a maintenance infusion at 0.1 μg/kg/min until 24 hours postoperatively.

  • DrugPlacebo

    Following endovascular treatment, patients receive normal saline placebo, with the dosage calculated in the same manner as that of tirofiban in the experimental group.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with mRS 0-2

    Proportion of patients with Modified Rankin Scale (mRS) 0-2, Modified Rankin Scale(0-6), A lower MRS score indicates better functional status for the patient.

    Time frame: 90±7 days

Secondary outcomes

  1. Change in NIHSS score from baseline

    Change in National Institute of Health stroke scale score from baseline.The NIH Stroke Scale (NIHSS) score ranges from 0 to 42 points, with lower scores indicating better neurological function

    Time frame: 36±12 hours post-randomization

  2. Vascular recanalization rate assessed by CT/MR angiography

    Vascular recanalization rate assessed by CT/MR angiography

    Time frame: 36±12 hours post-randomization

  3. Change in infarct volume

    Change in infarct volume

    Time frame: 7±3 days post-randomization or discharge

  4. Distribution of mRS scores

    Modified Rankin Scale(0-6), A lower MRS score indicates better functional status for the patient.

    Time frame: 7±3 days/discharge;90±7 days post-randomization

  5. Proportion of patients achieving mRS 0-1

    Proportion of patients achieving mRS 0-1

    Time frame: 90±7 days

  6. Proportion of patients achieving mRS 0-3

    Proportion of patients achieving mRS 0-3

    Time frame: 90±7 days

  7. Incidence of Pharmacologic rescue therapy

    Incidence of Pharmacologic rescue therapy

    Time frame: 90±7 days

  8. Incidence of rescue therapy

    Incidence of rescue therapy

    Time frame: 90±7 days

  9. EQ-5D-5L utility score

    The EuroQol 5-Dimension 5-Level Utility Score (EQ-5D-5L utility score) ranges from -0.594 to 1.000 (Chinese value set), assessing health-related quality of life, with higher scores indicating better health status.

    Time frame: 90±7 days

  10. Probability of symptomatic intracranial hemorrhage

    Probability of symptomatic intracranial hemorrhage (Heidelberg Standards)

    Time frame: 48 hours

  11. All-cause mortality

    All-cause mortality

    Time frame: 90±7 days post-randomization

  12. Probability of any intracranial hemorrhage

    Probability of any intracranial hemorrhage (Heidelberg Standards)

    Time frame: 48 hours post-randomization

07

Study locations

1 of 1 sites recruiting
  • Beijing Anzhen Hospital Affiliated to Capital Medical University
    Beijing, Beijing Municipality 101118, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 18 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 18, 2025
StartActual
Aug 15, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07026318
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Aug 15, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Sep 22, 2025

Study contacts

Xiaochuan Huo, Doctor
Contact
hxc810909@163.com
+86 13716292262
Xin Tong, Doctor
Contact
tomice123@foxmail.com
+86 17810651085

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirofiban

Start the discussion